# To Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF)

> **NCT06264310** · PHASE2 · COMPLETED · sponsor: **River 2 Renal Corp.** · enrollment: 33 (actual)

## Conditions studied

- Heart Failure
- Worsening Heart Failure (WHF)

## Interventions

- **DRUG:** Placebo
- **DRUG:** R2R01

## Key facts

- **NCT ID:** NCT06264310
- **Lead sponsor:** River 2 Renal Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-01
- **Primary completion:** 2024-11-04
- **Final completion:** 2024-11-25
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2024-11-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06264310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06264310, "To Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF)". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06264310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*